BioSpace News Archive

Biotech Bay

Augmedix Announces Participation in Maxim Group Healthcare IT Investor Conference on January 25

Augmedix Inc. (Nasdaq: AUGX) today announced that its leadership team will participate in the Maxim Group Virtual Healthcare IT Conference on Wednesday, January 25, 2023.

January 18, 2023
·
1 min read
Biotech Bay

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.

January 18, 2023
·
1 min read
Drug Development

Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).

January 18, 2023
·
4 min read
Genetown

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of 96,700 restricted stock units to four new employees.

January 18, 2023
·
1 min read
Drug Development

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies.

January 18, 2023
·
10 min read
Drug Development

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Plus Therapeutics, Inc. today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium ( 186 Re) obisbemeda for the treatment of recurrent glioblastoma (GBM).

January 18, 2023
·
7 min read
Deals

Avulux and Axon Optics join forces, offering the world’s only lens clinically proven to block harmful light linked to migraine attacks

Avulux is pleased to announce that Axon Optics is now part of the Avulux family.

January 18, 2023
·
1 min read
Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023

Asep Medical Holdings Inc. is pleased to announce that it is holding an online webinar on January 24, 2023, at 1:00 pm EST to provide essential and exciting updates on the company’s global market developments, scientific advances and investment-related milestones.

January 18, 2023
·
5 min read
Business

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

OpGen, Inc. today announced preliminary unaudited revenue for 2022.

January 18, 2023
·
6 min read
Business

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Arch Therapeutics, Inc. today announced the formation of a medical advisory board (the “ Medical Advisory Board ”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery.

January 18, 2023
·
5 min read